Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs F8 IL10 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Philogen
- 08 Mar 2024 This trial has been Discontinued in Italy (End Date: 2020-02-19) according to European Clinical Trials Database record.
- 22 Jun 2023 This study has been completed in German (End Date: 2023-06-08), according to European Clinical Trials Database.
- 09 Jun 2023 Status changed from active, no longer recruiting to discontinued because approvals of new agents for the same indication have significantly slowed down the recruitment in this trial making the prosecution of the present investigation extremely difficult.